Challenges Of Pharmacoeconomics In Global Health Arena

The pace of globalization has significantly accelerated since the end of the Cold War Era in 1989. These changes profoundly affected health care systems worldwide. Health policy makers increasingly started facing new harsh challenges in their uneasy task to provide universal health coverage and decent equity of access to medical services. Among the most prominent demand-side issues are extended longevity joined with population aging, rise of non-communicable diseases, and growing patient expectations. Supply-side causes are gains in societal welfare and living standards, technological innovation in medicine and continuing rapid urbanization in developing world regions. Successful insurance-based risk sharing agreements made drug dispensing and medical service provision cheap or virtually free at the point of consumption in most OECD and many middle-income countries. Coupled with massive build-up of workforce capacities and strengthening of primary care and hospital networks, all these factors contributed to the “supplier induced demand” phenomenon. There is straightforward historical evidence of long-term growth in pharmaceutical and overall health spending both in absolute and GDP% terms worldwide. The accumulated constraints deriving from skyrocketing costs of care were felt in many areas of clinical medicine even among the richest societies. Cardinal examples of expensive and hardly affordable therapeutic areas are orphan drugs indicated to treat rare diseases and targeted biologicals used in autoimmune disorders and cancer. Last but not least, is troubled and frequently denied access to even essential generic pharmaceuticals still taking place in many nations. This appears to be particularly the case among the world's poor and under-served citizens residing in rural and suburban areas of low- and middle-income countries. To a large extent, these difficulties are worsened by lack of evidence-based resource allocation strategies and less sustainable financing strategies.

The pharmaceutical industry is almost boundless in its ability to supply new drug therapies, but how does one decide which are the best medicines to use within restricted budgets? With particular emphasis on modeling, methodologies, data sources, and application to real-world dilemmas, Pharmacoeconomics: From Theory to Practice provides an introduc

Defining the value in health care and elaborating appropriate value-propositions for health care beneficiaries poses numerous empirical and normative challenges. Different methods of Health Technology Assessments (HTAs) embedded in various interdisciplinary approaches of defining the value of health care have been established in recent years. Current initiatives aim to develop and combine transnational attempts to define an overall acceptable range for value-based healthcare interventions. In this book international scholars with background in medicine, philosophy, health-economics and further disciplines, who participated in an interdisciplinary conference in 2019 combine in-depth analyses with reflections informed by multidisciplinary debates on a pressing issue in healthcare.

While much progress has been made on achieving the Millenium Development Goals over the last decade, the number and complexity of global health challenges has persisted. Growing forces for globalization have increased the interconnectedness of the world and our interdependency on other countries, economies, and cultures. Monumental growth in international travel and trade have brought improved access to goods and services for many, but also carry ongoing and ever-present threats of zoonotic spillover and infectious disease outbreaks that threaten all. Global Health and the Future Role of the United States identifies global health priorities in light of current and emerging world threats. This report assesses the current global health landscape and how challenges, actions, and players have evolved over the last decade across a wide range of issues, and provides recommendations on how to increase responsiveness, coordination, and efficiency â€" both within the U.S. government and across the global health field.

Developing Global Health Programming: A Guidebook for Medical and Professional Schools, 2nd edition is an essential text for any academic institution, administrator, faculty, or student interested in developing or expanding global health education and international programs. This text expands on the 1st edition and provides a comprehensive view of global health education that is useful for medical, nursing, dental, public health, and other professional schools. This book provides evidence, theory, and practical information to guide astute program development and gold standard practices. Topics covered include ethics, pre-departure training, competencies, partnership structures, and much more. In addition, need-to-know resources and networking opportunities are detailed. This authoritative text has over 90 contributors, including trainee authors guided by faculty editors through a mentorship model. Foreword by Andre Jacques Neusy, Co-Founder & CEO, Training for Health Equity Network (THEnet)

Discover How to Apply DES to Problems Encountered in HTADiscrete event simulation (DES) has traditionally been used in the engineering and operations research fields. The use of DES to inform decisions about health technologies is still in its infancy. Written by specialists at the forefront of this area, Discrete Event Simulation for Health Techno

The pharmaceutical industry faces a well-documented perfect storm: on the one hand, the patent cliff; the lack of new blockbusters and, on the other, economic pressure on pricing from markets with growing expectations and shrinking budgets. In the face of such pressure, traditional health economics models no longer seem appropriate and yet what do we have to replace them? The growing focus on 'value' and 'cost effectiveness' are evidence of new emerging thinking although, even here, with the shift from medicine as cure to medicine as palliative, as a treatment for chronic illness and with the growing emphasis on preventative approaches, the landscape is complex and challenging. The Future of Health Economics offers a window into some of the most influential emerging issues in pharmacoeconomics; issues such as risk-sharing and alternative pricing models or the potential impact of radical new approaches such as personalized medicine; as well as exploring the changing role of government and regulators. Ulf Staginnus and Olivier Ethgen, themselves two of the most well-regarded practitioners in this field, have brought together some leading-edge thinkers from industry and academia around the world to provide the industry, policy-makers, regulators, health practitioners and academics with the raw material for their future scenarios.

Large catastrophic events, or rare acute events, may cause situations in which a local jurisdiction's medicines and medical supplies are not sufficient to provide care to the population it serves. In these cases of natural or engineered disasters, such as a terrorist attack, influenza pandemic, or earthquake, state or local authorities can request that the federal government provide assets from the Strategic National Stockpile to augment the state and local jurisdictions' resources. The Centers for Disease Control and Prevention's (CDC's) Strategic National Stockpile (SNS) is the nation's repository of antibiotics, chemical antidotes, antitoxins, vaccines, antiviral drugs, and other medical materiel designed to supplement and resupply state and local public health agencies in the event of an emergency. The materiel is intended to support national health security and is managed by the Office of Public Health Preparedness and Response's (OPHPR's) Division of Strategic National Stockpile (DSNS). The stated mission of the SNS is to prepare and support partners and provide the right resources at the right time to secure the nation's health. The National Academies of Sciences, Engineering, and Medicine organized a two-day public workshop to explore opportunities to improve the efficiency, effectiveness, and sustainable methods used by the CDC's SNS to distribute medical countermeasures and other supplies during disasters and other public health emergencies, especially those which result in disruption of physical infrastructure such as the electrical grid, central roadways, bridges, and tunnels within the impacted community. Participants explored relevant distribution lessons learned from other federal agency stockpiles and the private sector as well as opportunities to develop public-private collaborations in the purchase, warehousing, management, and distribution of medical countermeasures. This report summarizes the presentations and discussions from the workshop.